Equillium, Inc. (EQ) Bruce Steel, CEO

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile.

Bruce Steel, CEO

Next Episode All Episodes Previous Episode

Listen for free

RSS Feed Apple Podcasts Spotify Pocket Casts

About the Podcast

The Wall Street Resource

Your resource for microcap discovery and due diligence

As part of the investment process, we have conducted countless CEO and executive interviews, and found this to be an invaluable use of time. We provide The Wall Street Resource, not only to help you leverage your time, but for discovery and a starting point for due diligence.

About your host

Jeffrey Kone

Managing Member and portfolio manager of a micro-cap fund for over 15 years. Securities experience that encompasses almost all aspects of the industry (buy side, sell side, retail, institutional and investment banking). Degree from University of Southern California with a Bachelor of Science in Business, emphasis in Entrepreneurship.